368 A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients

✍ Scribed by C. Weekes; D.D. Von Hoff; A.A. Adjei; L. Yeh; D. Leffingwell; B. Sheedy; C. Iverson; P. Rajagopalan; R. Dubowy; N. Clendeninn

• Book ID: 119603051
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 45 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)72075-9